BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Rating of “Moderate Buy” by Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $36.5714.

A number of equities research analysts recently issued reports on BIOA shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioAge Labs in a research report on Monday, August 3rd. Finally, Roth Capital reiterated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a report on Friday, July 31st.

Institutional Trading of BioAge Labs

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in BioAge Labs in the third quarter valued at approximately $27,000. CWM LLC grew its stake in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of BioAge Labs in the 2nd quarter valued at $64,000. Finally, Bank of America Corp DE raised its stake in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares during the period.

BioAge Labs Trading Down 6.8%

BioAge Labs stock opened at $10.67 on Wednesday. The stock has a fifty day moving average price of $19.81 and a 200 day moving average price of $19.04. BioAge Labs has a 52 week low of $4.33 and a 52 week high of $25.95. The firm has a market capitalization of $489.75 million, a P/E ratio of -4.48 and a beta of 0.93.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million during the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, equities analysts predict that BioAge Labs will post -2.45 EPS for the current year.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.